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Abstract 
Medicinal plants used in folk medicine are being increasingly studied and used on 
pharmaceutical, food and nutraceutical fields. Herein, wild and commercial samples of 
Achillea millefolium L. (yarrow) were chemically characterized with respect to their 
macronutrients, free sugars, organic acids, fatty acids and tocopherols. Furthermore, in 
vitro antioxidant properties (free radicals scavenging activity, reducing power and lipid 
peroxidation inhibition) and antitumour potential (against breast, lung, cervical and 
hepatocellular carcinoma cell lines) of their methanolic extract, infusion and decoction 
(the most consumed forms) was evaluated and compared to the corresponding phenolic 
profile obtained by high performance liquid chromatography and mass spectrometry. 
Data obtained showed that the chemical profiles of wild and commercial samples, and 
also their methanolic extract, infusion and decoction were similar, varying only in the 
quantities found. Commercial yarrow have higher content of fat and saturated fatty 
acids, proteins, ash, energy value, sugars and flavonoids, while the wild sample revealed 
higher levels of carbohydrates, organic acids, unsaturated fatty acids, tocopherols and 
phenolic acids. The heterogeneity among the antioxidant and antitumour results of the 
samples and some low correlations with total phenolic compounds indicates that 
specific compounds, rather than the totality of them, are involved in the bioactive 
properties of samples. 
 
 
Keywords: Achillea millefolium L.; Wild/commercial; Chemical composition; Bioactive 
properties; Phytochemicals 
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1. Introduction 
In a society increasingly concerned with health and nutrition, medicinal plants emerge 
as alternative to synthetic products, used not only in traditional medicine but also in a 
number of food and pharmaceutical products, due to their nutritional properties and 
bioactivity (Phillipson, 2007). Achillea millefolium L., commonly known as yarrow, 
belongs to Asteraceae family and it is very common in mountain meadows, pathways, 
crop fields and homegardens. Its infusion or alcohol extract is widely used in Europe as 
a remedy to treat digestive problems, diabetes, hepato-biliary diseases and amenorrhea, 
and also consumed for its antitumour, antimicrobial, anti-inflammatory and antioxidant 
properties, among others (Baretta et al., 2012; Candan et al., 2010; Carvalho, 2010, 
Cavalcanti et al., 2006; Dall’Acquaa, Bolegob, Cignarellab, Gaionb, & Innocentia, 
2011; Jonsdottir, Omarsdottird, Vikingssona, Hardardottirc, & Freysdottir, 2011; 
Potrich et al., 2010; Trumbeckaite et al., 2011). The decoction is used for digestive and 
intestinal disorders, but it is also used externally for skin and mucosa inflammations 
(Rauchensteiner, Nejati & Saukel, 2004).  
Antioxidant properties of A. millefolium have previously been reported in 
hydroalcoholic, methanolic and aqueous extracts, as also in the essential oil (Candan et 
al., 2010; Kintzios, Papageorgiou, Yiakoumettis, Baričevič, & Kušar, 2010; 
Trumbeckaite et al., 2011; Vitalini et al., 2011), but not in the infusion or decoction, the 
most consumed form. Cytotoxicity against human tumour cell lines was also only 
evaluated with the ethanolic extract (Ghavami, Sardari, & Shokrgozar, 2010) and was 
related to the presence of sesquiterpene lactones and flavonols (Csupor-Löffler et al., 
2009). Antioxidant molecules such as tocopherols and ascorbic acid were quantified in 
A. millefolium and found to be present in considerable amounts (Chanishvili, Badridze, 
Rapava, & Janukashvili, 2007). Flavonoids, apigenin and quercetin, and the phenolic 
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acid, caffeoylquinic acid, were reported as the major phenolic compounds present in 
yarrow plant (Benedek, Gjoncaj, Saukel, & Kopp, 2007; Benetis, Radušienė, & Janulis, 
2008; Radušienė, 2011; Vitalini et al., 2011). The above mentioned compounds have 
the capacity to function as reducing agents, hydrogen donators or singlet oxygen 
quenchers against reactive species involved in oxidative stress, the main cause for cell 
death (Carocho & Ferreira, 2013).  
The main objective of the present work was to compare chemical composition of wild 
and commercial A. millefolium regarding macronutrients, free sugars, organic acids, 
fatty acids and tocopherols. Furthermore, in vitro antioxidant properties (free radicals 
scavenging activity, reducing power and lipid peroxidation inhibition) and antitumour 
potential (against breast, lung, cervical and hepatocellular carcinoma cell lines) of their 
methanolic extract, infusion and decoction (the most consumed forms) were evaluated 
and compared to the corresponding phenolic profile.   
 
2. Materials and methods 
2.1 Samples 
The wild yarrow (inflorescences and upper leaves) was collected in Cova de Lua, 
Bragança, Portugal from 50 plants growing in two different grasslands of about one 
hectare. The gathered material was mixed, made into a unique sample and further 
lyophilized (FreeZone 4.5, Labconco, Kansas City, MO, USA). A voucher specimen 
was deposited at the Herbarium of the Escola Superior Agrária de Bragança (BRESA). 
The commercial yarrow was purchased from a local company, Ervital from Castro 
Daire, Portugal, which produces Mediterranean herbs using organic principles and 
methods. Each sample was reduced to a fine dried powder (20 mesh) and mixed to 
obtain homogenate sample.  
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2.2 Standards and Reagents 
Acetonitrile (99.9%), n-hexane (95%) and ethyl acetate (99.8%) were of HPLC grade 
from Fisher Scientific (Lisbon, Portugal). Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) and the fatty acids methyl ester (FAME) 
reference standard mixture 37 (standard 47885-U) were purchased from Sigma (St. 
Louis, MO, USA), as well as other individual fatty acid isomers, L-ascorbic acid, 
tocopherol, sugar and organic acid standards. Phenolic standards were from 
Extrasynthèse (Genay, France). Racemic tocol (50 mg/mL), was purchased from 
Matreya (Pleasant Gap, PA, USA). 2,2-Diphenyl-1- picrylhydrazyl (DPPH) was 
obtained from Alfa Aesar (Ward Hill, MA, USA). Fetal bovine serum (FBS), L-
glutamine, hank’s balanced salt solution (HBSS), trypsin-EDTA 
(ethylenediaminetetraacetic acid), penicillin/streptomycin solution (100 U/mL and 100 
mg/mL, respectively), RPMI-1640 and DMEM media were from Hyclone (Logan, UT, 
USA). Acetic acid, ellipticine, sulphorhodamine B (SRB), trypan blue, trichloroacetic 
acid (TCA) and Tris were from Sigma Chemical Co. (Saint Louis, MO, USA). Water 
was treated in a Milli-Q water purification system (TGI Pure Water Systems, 
Greenville, SC, USA).  
 
2.3. Chemical composition of wild and commercial samples 
2.3.1. Macronutrients. The samples were analysed for proteins, fat, carbohydrates and 
ash using the AOAC (1995) procedures. The crude protein content (N×6.25) of the 
samples was estimated by the macro-Kjeldahl method; the crude fat was determined by 
extracting a known weight of powdered sample with petroleum ether, using a Soxhlet 
apparatus; the ash content was determined by incineration at 600±15 oC. Total 
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carbohydrates were calculated by difference. Energy was calculated according to the 
following equation: Energy (kcal) = 4 × (g protein) + 3.75 × (g carbohydrate) + 9 × (g 
fat).  
 
2.3.2. Sugars. Free sugars were determined by high performance liquid chromatography 
coupled to a refraction index detector (HPLC-RI), after an extraction procedure 
previously described (Guimarães et al., 2013a) using melezitose as internal standard 
(IS). The equipment consisted of an integrated system with a pump (Knauer, Smartline 
system 1000, Berlin, Germany), degasser system (Smartline manager 5000), auto-
sampler (AS-2057 Jasco, Easton, MD, USA) and an RI detector (Knauer Smartline 
2300, Berlin, Germany). Data were analysed using Clarity 2.4 Software (DataApex). 
The chromatographic separation was achieved with a Eurospher 100-5 NH2 column (4.6 
× 250 mm, 5 mm, Knauer, Berlin, Germany) operating at 30 ºC (7971 R Grace oven). 
The mobile phase was acetonitrile/deionized water, 70:30 (v/v) at a flow rate of 1 
mL/min. The compounds were identified by chromatographic comparisons with 
authentic standards. Quantification was performed using the internal standard method 
and sugar contents were further expressed in g per 100 g of dry weight. 
 
2.3.3. Organic acids. Organic acids were determined following a procedure previously 
described (Pereira, Barros, Carvalho, & Ferreira, 2013). The analysis was performed 
using a Shimadzu 20A series UFLC (Shimadzu Corporation, Kyoto, Japan). Separation 
was achieved on a SphereClone (Phenomenex, Torrance, CA, USA) reverse phase C18 
column (5 µm, 250 mm × 4.6 mm i.d.) thermostatted at 35 ºC. The elution was 
performed with sulphuric acid (3.6 mM) using a flow rate of 0.8 mL/min. Detection was 
carried out in a PDA, using 215 and 245 nm (for ascorbic acid) as preferred 
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wavelengths. The organic acids found were quantified by comparison of the area of 
their peaks recorded at 215 nm with calibration curves obtained from commercial 
standards of each compound. The results were expressed in g per 100 g of dry weight.  
 
2.3.4. Fatty acids. Fatty acids were determined by gas-liquid chromatography with 
flame ionization detection (GC-FID)/capillary column as described previously 
(Guimarães et al., 2013a). The analysis was carried out with a DANI model GC 1000 
instrument (Contone, Switzerland), equipped with a split/splitless injector, a flame 
ionization detector (FID at 260 ºC) and a Macherey–Nagel (Düren, Germany) column 
(50% cyanopropyl-methyl-50% phenylmethylpolysiloxane, 30 m × 0.32 mm i.d. × 0.25 
μm df).. The oven temperature program was as follows: the initial temperature of the 
column was 50 ºC, held for 2 min, then a 30 ºC/min ramp to 125 ºC, 5 ºC/min ramp to 
160 ºC, 20 ºC/ min ramp to 180 ºC, 3 ºC/min ramp to 200 ºC, 20 ºC/min ramp to 220 ºC 
and held for 15 min. The carrier gas (hydrogen) flow-rate was 4.0 mL/min (0.61 bar), 
measured at 50 ºC. Split injection (1:40) was carried out at 250 ºC. Fatty acid 
identification was made by comparing the relative retention times of FAME peaks from 
samples with standards. The results were recorded and processed using the CSW 1.7 
Software (DataApex 1.7) and expressed in g/100 g fat. 
 
2.3.5. Tocopherols. Tocopherols were determined following a previously described 
procedure (Guimarães et al., 2013a). Analysis was performed by HPLC (equipment 
described above), and a fluorescence detector (FP-2020; Jasco, Easton, MD, USA) 
programmed for excitation at 290 nm and emission at 330 nm. The chromatographic 
separation was achieved with a Polyamide II (250 mm × 4.6 mm i.d.) normal-phase 
column from YMC Waters (Dinslaken, Germany) operating at 30 ºC. The mobile phase 
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used was a mixture of n-hexane and ethyl acetate (70:30, v/v) at a flow rate of 1 
mL/min, and the injection volume was 20 µL. The compounds were identified by 
chromatographic comparisons with authentic standards. Quantification was based on 
calibration curves obtained from commercial standards of each compound using the 
internal standard (IS) methodology; racemic tocol was used as IS. The results were 
expressed in mg per 100 g of dry weight.  
 
2.4. Bioactivity and phenolic profile of the methanolic extract, infusion and decoction 
2.4.1. Samples preparation. The methanolic extract was obtained from the lyophilized 
wild and commercial plant material. Each sample (1 g) was extracted twice by stirring 
with 30 mL of methanol (25 ºC at 150 rpm) for 1 h and subsequently filtered through a 
Whatman No. 4 paper. The combined methanolic extracts were evaporated at 40 ºC 
(rotary evaporator Büchi R-210, Flawil, Switzerland) to dryness.  
For infusion preparation the lyophilized plant material (1 g) was added to 200 mL of 
boiling distilled water and left to stand at room temperature for 5 min, and then filtered 
under reduced pressure. For decoction preparation the lyophilized plant material (1 g) 
was added to 200 mL of distilled water, heated (heating plate, VELP scientific) and 
boiled for 5 min. The mixture was left to stand for 5 min and then filtered under reduced 
pressure. The obtained infusions and decoctions were frozen and lyophilized. 
Methanolic extracts and lyophilized infusions and decoctions were redissolved in i) 
methanol and water, respectively (final concentration 2.5 mg/mL) for antioxidant 
activity evaluation, ii) water (final concentration 8 mg/mL) for antitumour potential 
evaluation; and iii) water:methanol (80:20, v/v) and water, respectively (final 
concentration 1 mg/mL) for phenolic compounds identification and quantification. The 
final solutions were further diluted to different concentrations to be submitted to distinct 
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bioactivity evaluation in in vitro assays. The results were expressed in i) EC50 values 
(sample concentration providing 50% of antioxidant activity or 0.5 of absorbance in the 
reducing power assay) for antioxidant activity, or ii) GI50 values (sample concentration 
that inhibited 50% of the net cell growth) for antitumour potential. Trolox and 
ellipticine were used as positive controls in antioxidant and antitumour activity 
evaluation assays, respectively. 
 
2.4.2. Antioxidant activity. DPPH radical-scavenging activity was evaluated by using an 
ELX800 microplate reader (Bio-Tek Instruments, Inc; Winooski, VT, USA), and 
calculated as a percentage of DPPH discolouration using the formula: [(ADPPH-
AS)/ADPPH] × 100, where AS is the absorbance of the solution containing the sample at 
515 nm, and ADPPH is the absorbance of the DPPH solution. Reducing power was 
evaluated by the capacity to convert Fe3+ to Fe2+, measuring the absorbance at 690 nm 
in the microplate reader mentioned above. Inhibition of β-carotene bleaching was 
evaluated though the β-carotene/linoleate assay; the neutralization of linoleate free 
radicals avoids β-carotene bleaching, which is measured by the formula: β-carotene 
absorbance after 2h of assay/initial absorbance) × 100. Lipid peroxidation inhibition in 
porcine (Sus scrofa) brain homogenates was evaluated by the decreasing in 
thiobarbituric acid reactive substances (TBARS); the colour intensity of the 
malondialdehyde-thiobarbituric acid (MDA-TBA) was measured by its absorbance at 
532 nm; the inhibition ratio (%) was calculated using the following formula: [(A - B)/A] 
× 100%, where A and B were the absorbance of the control and the sample solution, 
respectively (Guimarães et al., 2013b). 
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2.4.3. Antitumour potential and cytotoxicity in non-tumour liver primary cells. Five 
human tumour cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-
small cell lung cancer), HCT-15 (colon carcinoma), HeLa (cervical carcinoma) and 
HepG2 (hepatocellular carcinoma). Cells were routinely maintained as adherent cell 
cultures in RPMI-1640 medium containing 10% heat-inactivated FBS and 2 mM 
glutamine (MCF-7, NCI-H460 and HCT-15) or in DMEM supplemented with 10% 
FBS, 2 mM glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin (HeLa and 
HepG2 cells), at 37 ºC, in a humidified air incubator containing 5% CO2. Each cell line 
was plated at an appropriate density (7.5 × 103 cells/well for MCF-7, NCI-H460 and 
HCT-15 or 1.0 × 104 cells/well for HeLa and HepG2) in 96-well plates. 
Sulphorhodamine B assay was performed according to a procedure previously described 
by the authors (Guimarães et al., 2013b). 
For hepatotoxicity evaluation, a cell culture was prepared from a freshly harvested 
porcine liver obtained from a local slaughter house, according to an established 
procedure (Guimarães et al., 2013b); it was designed as PLP2. Cultivation of the cells 
was continued with direct monitoring every two to three days using a phase contrast 
microscope. Before confluence was reached, cells were subcultured and plated in 96-
well plates at a density of 1.0×104 cells/well, and commercial in DMEM medium with 
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. 
 
2.4.4. Phenolic profile. Phenolic compounds were determined by HPLC (Hewlett-
Packard 1100, Agilent Technologies, Santa Clara, CA, USA) as previously described by 
the authors (Rodrigues et al., 2012). Double online detection was carried out in the 
diode array detector (DAD) using 280 and 370 nm as preferred wavelengths and in a 
mass spectrometer (API 3200 Qtrap, Applied Biosystems, Darmstadt, Germany) 
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connected to the HPLC system via the DAD cell outlet. The phenolic compounds were 
characterized according to their UV, mass spectra, retention times, and comparison with 
authentic standards when available. For quantitative analysis, a 5-level calibration curve 
was obtained by injection of known concentrations (2.5-100 µg/mL) of different 
standards compounds: apigenin-6-C-glucoside (y=246.05x-309.66; R2=0.9994); 
apigenin-7-O-glucoside (y=159.62x+70.50; R2=0.999); caffeic acid (y=611.9x-4.5733; 
R2=0.999); 5-O-caffeoylquinic acid (y=313.03x-58.20; R2=0.999); kaempferol-3-O-
glucoside (y=288.55x-4.05; R2=1); kaempferol-3-O-rutinoside (y=239.16x-10.587; 
R2=1); luteolin-6-C-glucoside (y=508.54x-152.82; R2=0.997); luteolin-7-O-glucoside 
(y=80.829x-21.291; R2=0.999); quercetin-3-O-glucoside (y=253.52x-11.615; R2=0.999) 
and quercetin-3-O-rutinoside (y=281.98x-0.3459; R2=1). The results were expressed in 
mg per g of methanolic extract and lyophilized infusion or decoction. 
 
2.5. Statistical analysis 
For wild and commercial plant material, three samples were used and all the assays 
were carried out in triplicate. The results are expressed as mean values and standard 
deviation (SD). The results were analyzed using one-way analysis of variance 
(ANOVA) followed by Tukey’s HSD Test with α = 0.05. This treatment was carried out 
using SPSS v. 18.0 program.  
 
3. Results and Discussion 
 
3.1 Chemical composition of wild and commercial samples 
The chemical composition of wild and commercial A. millefolium in macronutrients, 
free sugars and organic acids is presented in Table 1.  
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Carbohydrates, followed by proteins, were the major macronutrients in both samples. 
The commercial sample revealed higher contents of all the macronutrients except in 
carbohydrates which were higher in the wild yarrow. Fructose, glucose, sucrose and 
trehalose were found in both samples, while raffinose was only detected in the wild 
sample. Commercial sample also showed the highest levels of individual and total free 
sugars. Wild sample presented the highest content in total organic acids, mainly oxalic, 
quinic, and citric; succinic acid was not detected in the commercial sample and fumaric 
acid was only found in traces (Table 1).  
Up to twenty-nine fatty acids were identified on wild and commercial A. millefolium 
(Table 2). In both samples linoleic acid (C18:2n-6, PUFA) was the major fatty acid, 
followed by palmitic acid (C16:0, SFA) in the case of  commercial sample, and oleic 
acid (C18:1n-9, PUFA) in the case of wild sample. The wild sample gave higher levels 
of PUFA (with the major contribution of linoleic acid) and MUFA (mainly due to oleic 
acid), while the commercial sample showed the highest levels of SFA (with the 
important contribution of palmitic acid).  
Although both samples presented similar tocopherol profile (α-, β-­‐,	   and	   γ- isoforms), 
wild yarrow presented higher levels of total tocopherols (Table 2), γ-tocopherol being 
the most abundant isoform. δ-Tocopherol was not found in the samples. Chanishvili et 
al. 2007 previously reported the presence of tocopherols in A. millefolium samples from 
Georgia, but without quantification of the individual isoforms.  
 
3.2 Bioactivity of the methanolic extract, infusion and decoction 
Antioxidant properties of the methanolic extract and of the most consumed forms of A. 
millefolium, infusion and decoction, were evaluated and the results are shown in Table 
3. In general, commercial yarrow presented lower EC50 values (higher antioxidant 
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activity). In both cases (wild and commercial samples), decoctions showed the highest 
DPPH scavenging activity, β-carotene bleaching inhibition and TBARS inhibition, 
while infusions presented the highest reducing power. 
The samples herein studied gave lower DPPH scavenging activity than water and 
methanolic extracts of A. millefolium from Slovenia and Lithuania (Kintzios et al., 
2010; Trumbeckaite et al., 2011). They also showed lower DPPH scavenging activity 
but higher lipid peroxidation inhibition than methanolic extracts of A. millefolium from 
Turkey (45.60 and 892.67 µg/mL, respectively; Candan et al., 2010). These variations 
cab be either due to intrinsic factors, mainly genetics or to extrinsic factors, such as 
storage, type of soil, agronomic practices, climatic factors and technological treatments 
(Ghasemnezhad, Sherafati, & Payvast, 2011). 
The effects of the methanolic extracts, infusions and decoctions on different human 
tumour cell lines (MCF-7, NCI-H460, HCT-15, HeLa and HepG2) were also evaluated 
(Table 3). The infusion of wild yarrow showed the highest potential against breast 
(MCF-7; in this case the methanolic extract gave statistically similar results) and 
hepatocellular (HepG2) carcinoma cell lines, while the methanolic extract of 
commercial yarrow was most potent against lung (NCI-H460), colon (HCT-15) and 
cervical (HeLa) carcinoma cell lines. Although the samples present some toxicity for 
non-tumour liver primary cells (PLP2), the GI50 values obtained for tumour cell lines 
(HepG2) were always lower than the hepatotoxic GI50 concentration, suggesting that the 
samples could be used for antitumour proposes, at the GI50 concentration, without toxic 
effects for non-tumour cells. The results reported for MCF-7 cell line, mainly in the 
case of decoction and infusion of the commercial sample, are consistent with the ones 
obtained with ethanolic extracts of A. millefolium from Iran (GI50=64.078	   μg/mL) 
(Ghavami et al., 2010). The antiproliferative activity against HeLa and MCF-7 tumour 
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cell lines of sesquiterpene lactones and flavonols isolated from A. millefolium samples 
from Hungary was also studied by Csupor-Löffler et al. (2009) and correlated to the 
activity of alcoholic and aqueous extracts of the plant.  
 
3.3. Phenolic profile of the methanolic extract, infusion and decoction  
The HPLC phenolic profile of a wild sample of A. millefolium recorded at 280 and 370 
nm is shown in Figure 1, and peak characteristics and identification are presented in 
Table 4. Twenty-eight compounds were detected, eight of which were phenolic acid 
derivatives (hydroxycinnamic acid derivatives). Among them, seven compounds (peaks 
1, 3, 4, 16, 19, 20 and 22) were caffeoylquinic acid derivatives identified according to 
their UV spectra and pseudomolecular ions. Peak 1 ([M-H]- at m/z 353) was identified 
as 3-O-caffeoylquinic acid, yielding the base peak at m/z 191 and the ion at m/z 179 
with an intensity >70% base peak, characteristic of 3-acylchlorogenic acids as reported 
by Clifford, Johnston, Knight, & Kuhnert (2003) and Clifford, Knight, & Kuhnert 
(2005). 
Peak 3 was easily distinguished from the other two isomers by its base peak at m/z 173 
[quinic acid-H-H2O]-, accompanied by a secondary fragment ion at m/z 179 with 
approximately 88% abundance of base peak, which allowed identifying it as 4-O-
caffeoylquinic acid according to the fragmentation pattern described by Clifford et al. 
(2003, 2005). Peak 4 was identified as 5-O-caffeoylquinic acid by comparison of its UV 
spectrum (λmax 326 nm) and retention time with a commercial standard. 
Peaks 16, 19, 20 and 22 ([M-H]- at m/z 515) corresponded to dicaffeoylquinic acids and 
were assigned to 3,4-O-, 3,5-O- and 4,5-O- dicaffeoylquinic acids, respectively, based 
on their elution order and fragmentation patterns (Clliford et al., 2003; Clliford et al., 
2005). MS2 fragmentation of peak 16 yielded signals corresponding to “dehydrated” 
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fragment ions at m/z 335 [caffeoylquinic acid-H-H2O]- and m/z 173 [quinic acid-H-
H2O]-, characteristic of 4-acyl-caffeoylquinic acids. Furthermore, according to Clifford 
et al. (2005), the intensity of signal at m/z 335 (34% of base peak), greater than in the 
other dicaffeoylquinic acids, would allow assigning compound 16 as 3,4-O-
dicaffeoylquinic acid. The fragmentation pattern of peaks 19 and 20 was similar to the 
one previously reported by Clifford et al. (2005) for 3,5-O-dicaffeoylquinic acid. MS2 
base peak was at m/z 353, produced by the loss of one of the caffeoyl moieties [M-H-
caffeoyl]-, and subsequent fragmentation of this ion yielded the same fragments as 5-
caffeoylquinic acid at m/z 191, 179 and 135, although in this case with a comparatively 
more intense signal at m/z 179 [caffeic acid-H]- (~70% base peak). These peaks 19 and 
20 were identified as cis and trans 3,5-O-dicaffeoylquinic acid, respectively, based on 
the elution order described in a previous study (Barros, Dueñas, Carvalho, Ferreira, & 
Santos-Buelga, 2012). Compound 22 was assigned to 4,5-O-dicaffeoylquinic acid 
according to its fragmentation, identical to the one previously reported by Clifford et al. 
(2005). Contrary to 3,4-O-dicaffeoylquinic acid (peak 16), in this case the signal at m/z 
335 was barely detectable (3% of base peak). The intense signal at m/z 173, 
characteristic of an isomer substituted at position 4, would indicate that whereas 3,4-O-
dicaffeoylquinic acid initially loses the caffeoyl moiety at position 3, the 4,5-O-
dicaffeoylquinic acid first loses that at position 5. Peak 2 ([M-H]- at m/z 341) was 
assigned as a caffeic acid hexoside based on the ion at m/z 179 (-162 u; hexosyl residue; 
[caffeic acid-H]-) and UV spectrum (λmax 326 nm).  
 
Flavones were also found in the studied samples, most of them associated to apigenin 
derivatives (nine compounds) according to their UV spectra (λmax around 330-340 nm) 
and MS2 fragmentation pattern (Table 4).  
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Apigenin 7-O-glucoside (peak 23) was positively identified according to their retention, 
mass and UV-vis characteristics by comparison with commercial standard. Peaks 5-7 
presented pseudomolecular ions [M-H]- at m/z 593 or 563, releasing MS2 fragment ions 
corresponding to loss of 90 and 120 u (m/z at 473 and 443), characteristic of C-hexosyl 
flavones, and at m/z 383 and 353 that might correspond to the apigenin aglycone plus 
residues of the sugars that remained linked to it (apigenin + 113 u) and (apigenin + 83 
u), respectively (Ferreres, Silva, Andrade, Seabra, & Ferreira, 2003). The fact that no 
relevant fragments derived from the loss of complete hexosyl (-162 u) or pentosyl 
residues (-132 u) were detected suggested that sugars were C-attached, which allowed 
an identification of these compounds as apigenin-C-hexoside-C-hexoside (Peak 5) and 
apigenin-C-hexoside-C-pentoside (peaks 6 and 7). 
Peaks 14 and 21 (also pseudomolecular ions at [M-H]- at m/z 593 and 563) could be 
assigned to an apigenin dihexoside and an apigenin O-pentosyl-hexoside, respectively, 
based on the loss of two hexosyl moieties (162+162 u) in the first case, and of pentosyl 
and hexosyl residues (132+162 u) in the second one, to yield the aglycone (m/z at 269, 
apigenin). The fact that the two moieties were lost simultaneously suggested that they 
might constitute a disaccharide O-linked to the aglycone.  
Peaks 26, 27 and 28, all of them with a pseudomolecular ion [M-H]- at m/z 473 
releasing a unique MS2 fragment at m/z 269 (apigenin; [M-H-42-162]-), were identified 
as apigenin O-acetylhexosides according to their mass, 42 u greater than apigenin-
hexoside. The observation of three peaks with the same characteristics could be 
explained by the location of the acetylhexoside moiety on different positions of the 
aglycone and/or the substitution of the acetyl residue on different positions of the 
hexose. The positive identification of apigenin 7-O-glucoside in the samples would 
point to one or all of these compounds could be derived from it. 
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Peaks 8 and 24 were assigned to luteolin derivatives. Peak 8 showed a pseudomolecular 
ion [M-H]- at m/z 447 giving place to three MS2 fragment ions, a major one at m/z 357 
[M-H-90]-, and other two at m/z 327 [M-H-120]- and at m/z 297 [M-H-30]-. The 
fragmentation pattern was characteristic of C-glycosylated flavones at C-6/C-8, and the 
relative abundance of fragments pointed out to sugar substitution at C-6 according to the 
fragmentation patterns described by Ferreres, Silva, Andrade, Seabra, & Ferreira 
(2003), Ferreres, Llorach, & Gil-Izquierdo (2004) and Ferreres, Gil- Izquierdo, 
Andrade, Valentao, & Tomás-Barberán (2007) The peak was identified as luteolin-6-C-
glucoside, which was further confirmed by comparison to a standard. Peak 24 ([M-H]- 
at 489 m/z) released a unique MS2 fragment at m/z 285 (luteolin; [M-H-42-162]-) which 
allowed its identification as luteolin O-acetylhexoside. 
The remaining phenolic compounds corresponded to flavonols derivatives, most of 
them derived from quercetin (λmax around 350 nm and an MS2 fragment at m/z 301) 
(Table 4). Quercetin 3-O-rutinoside (peak 13) was positively identified according to its 
retention, mass and UV-vis characteristics by comparison with a commercial standard. 
Peak 10 ([M-H]- at m/z 463) was assigned to a quercetin hexoside, although the position 
and nature of the hexosyl moiety could not be identified, because its retention time did 
not correspond to any of the standards available (quercetin 3-O-glucoside, Rt = 20.05 
min.). Peak 9 ([M-H]- m/z at 595) was assigned to a quercetin derivative bearing 
pentosyl and hexosyl residues, based on the loss of 294 u (132+162 u) to yield the 
aglycone (m/z at 301, quercetin). The fact that the two moieties were lost 
simultaneously suggested that they could constitute a disaccharide O-linked to the 
aglycone. Peaks 17 and 18 ([M-H]- at m/z 505) should correspond to quercetin O-
acetylhexosides according to their pseudomolecular ion and MS2 fragment released at 
m/z 301 (quercetin; [M-H-42-162]-, loss of an acetylhexoside moiety). 
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Peak 11 ([M-H]- at m/z 695) released a majority MS2 fragment at m/z 651 ([M-H-44]-) 
interpreted as the loss of CO2, coherent with the existence of a non-substituted carboxyl. 
The observation of other fragments at m/z 609 ([M-H-86]-) and 447 ([M-H-86-162]-) 
further support that supposition as they can be interpreted by the loss malonyl and 
malonylhexosyl residues, respectively. Finally, the fragment at m/z 301 ([M-H-86-162-
146])-; quercetin) would be explained by further loss of a rhamnosyl residue. The 
observation of fragments derived from the alternative loss of the malonylhexosyl and 
the rhamnosyl moieties could suggest that they were located at different positions on the 
aglycone; however, it might also be rationalised as a quercetin malonylhexosyl-
rhamnoside where the two sugars were constituting a disaccharide, in which case the 
fragment at m/z 447 should be explained by structural rearrangement following the loss 
of the internal malonylhexosyl residue and further linkage of the terminal rhamnose to 
the aglycone, as observed by (Ma, Li, Van den Heuvel, & Claeys, 1997). In that case, 
the presence in the samples of quercetin 3-O-rutinoside might point to peak 11 as 
quercetin 3-O-malonylrutinoside. 
Peak 12 ([M-H]- at m/z 579) was identified as a kaempferol derivative bearing pentosyl 
and hexosyl residues, owing to the loss of 132+162 u to yield a fragment ion at m/z at 
285 (kaempferol). The observation that no fragment from the loss of the pentosyl 
residue was observed pointed to the two sugars were constituting a disaccharide, and the 
minority fragment ion detected at m/z 417 (-162 u, hexosyl residue) suggests that the 
hexose was the terminal moiety of the disaccharide. Thus, the peak was identified as a 
kaempferol O-pentosyl-hexoside.  
Finally, peaks 15 and 25 presented pseudomolecular ions [M-H]- at m/z 477 and 519, 
which were coherent with an isorhamnetin O-hexoside and an isorhamnetin O-
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acetylhexoside, as indicated by the respective losses of 162 u and 162+42 u yielding a 
unique MS2 fragment ion at m/z 315 (isorhamnetin).  
 
Phenolic acids were the major phenolic compounds present in both wild and 
commercial samples (Table 5), being caffeoylquinic and dicaffeoylquinic acids 
derivatives the most abundant ones; cis and trans 3,5-O-dicaffeoylquinic acids (peaks 
20 and 21) were the compounds found in the highest amounts. Benedek et al. (2007) 
and Vitalini et al. (2011) also reported 3,5-O-dicaffeoylquinic acid as being the main 
dicaffeoylquinic acid in A. millefolium from Austria and Italy, respectively. Those 
authors also described a similar phenolic profile to the one obtain herein, although with 
some differences in the flavonoids identified, being apigenin 7-O-glucoside, luteolin 7-
O-glucoside and rutin the main flavonoids reported by them. In our samples luteolin O-
acetylhexoside and apigenin O-acetylhexoside (peaks 24 and 27) were the most 
abundant flavonoids in both wild and commercial samples. In fact, the presence of 
acetyl derivatives seems a characteristic of the flavonoid composition in these samples. 
In this study, besides the mentioned majority flavones, flavonols such as quercetin, 
kaempferol and isorhamnetin glycosides derivatives were also found, as also C-
glycosides linkage of apigenin and luteolin, which were not previously reported for this 
sample. In A. millefolium sample from Lithuania, Benetis et al. (2008) described the 
presence of some similar compounds but they did not identify all the compounds 
present; the authors identified and quantified only eight phenolic compounds.  
 
Regarding contents of total phenolic compounds and phenolic families, different results 
were obtained depending on the origin of the sample (wild or commercial) and the type 
of preparation (Table 5). Thus, whereas the methanolic extract of wild A. millefolium 
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presented higher amount of total phenolic compounds than the commercial sample, the 
opposite was found in the case of the decoction; infusion yielded more similar amounts 
of total phenolics in both samples. In all cases phenolic acid derivatives were more 
abundant than flavonoids, but the contents of these latter were greater in the commercial 
sample. Benedek et al. (2007) expressed the results in relative percentages, which 
difficults the comparison with our study; moreover, they reported the presence of 15 
compounds whilst 28 are described herein. Vitalini et al. (2011) did not present any type 
of quantification for samples of A. millefolium from Italy, presenting a profile with 10 
different compounds. Benetis et al. (2008) performed the identification and 
quantification of 8 phenolic compounds, which presented similar values to the ones 
obtained in our samples. 
 
Overall, commercial yarrow gave higher content of fat (and SFA), proteins, ash, 
energetic value, total sugars (including fructose, glucose, sucrose and trehalose) and 
flavonoids (mainly luteolin O-acetylhexoside and apigenin O-acetylhexoside), while the 
wild sample revealed higher levels of carbohydrates, organic acids (including malic, 
oxalic and quinic acids), unsaturated fatty acids, tocopherols (γ-, α- and β-isoforms) and 
phenolic acids (mainly cis and trans 3,5-O-dicaffeoylquinic acids). In general, 
commercial yarrow also gave higher antioxidant activity. The decoctions of both 
samples showed higher free radicals scavenging activity and lipid peroxidation 
inhibition, while the infusions gave higher reducing power. The methanolic extract of 
the commercial sample revealed higher antitumour potential against non-small lung, 
colon and cervical carcinoma cell lines, while the infusion of the wild yarrow gave 
higher antitumour potential against hepatocellular and breast carcinoma cell lines; for 
the latter cell line, the methanolic extract showed statistically similar results. The 
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opposite was observed for phenolic compounds concentrations: the methanolic extract 
of the wild sample revealed the highest levels, while for commercial sample the 
infusion gave the highest concentration. The heterogeneity among the bioactivity results 
of the samples and some low correlations with total phenolic acids, flavonoids and 
phenolic compounds (data not shown) suggested that specific compounds, rather than 
the totality of them, might be involved in different bioactive properties of samples; the 
bioactivity could also be related to interactions between specific compounds present in 
each sample. Moreover, as the most bioactive compounds may be present in lower 
amounts, further studies should be conducted in order to identify the specific 
compounds responsible for distinct bioactivities in the samples. 
 
As far as we know, there are no reports of the comparison of different extracts of A. 
millefolium, being this a groundbreaking study on the nutraceutical composition, 
bioactivity and phenolic profile of wild and commercial yarrow. This study also showed 
that the chemical qualitative profiles of wild and commercial samples, as also their 
preparations (i.e., methanolic extract, infusion and decoction) are, in general, similar, 
varying only in the quantities found. Data obtained are clear evidence that traditional 
medicinal plants can be used not only in household products but also in pharmaceutical 
and food industry as a source of new and safer bioactive compounds. 
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Table 1. Chemical composition of wild and commercial Achillea millefolium L. in 
macronutrients, free sugars and organic acids.  
 
 Wild sample Commercial sample 
Fat (g/100 g dw) 5.20 ± 0.13b 8.03 ± 0.00a 
Proteins (g/100 g dw) 12.53 ± 0.85b 19.53 ± 0.05a 
Ash (g/100 g dw) 6.43 ± 0.11b 8.54 ± 0.88a 
Carbohydrates (g/100 g dw) 75.84 ± 0.76a 63.90 ± 0.86b 
Energy (kcal/100 g dw) 400.28 ± 0.21b 405.99 ± 3.52a 
Fructose  1.11 ± 0.02b 1.31 ± 0.06a 
Glucose  0.66 ± 0.04b 1.43 ± 0.08a 
Sucrose  0.80 ± 0.03a 0.95 ± 0.11a 
Trehalose  0.42 ± 0.04b 1.18 ± 0.17a 
Raffinose  0.15 ± 0.00 nd 
Total sugars (g/100 g dw) 3.14 ± 0.08b 4.86 ± 0.29a 
Oxalic acid 1.08 ± 0.06a 0.92 ± 0.01b 
Quinic acid 0.69 ± 0.03b 1.50 ± 0.08a 
Malic acid 1.64 ± 0.04a 0.77 ± 0.13b 
Shikimic acid 0.02 ± 0.00a 0.02 ± 0.00a 
Citric acid 0.83 ± 0.03b 1.25 ± 0.13a 
Succinic acid 0.27 ± 0.03 nd 
Fumaric acid 0.03 ± 0.00 tr 
Total organic acids  (g/100g dw) 4.55 ± 0.10a 4.46 ± 0.19b 
 
nd- not detected; dw- dry weight. In each row different letters mean significant differences (p<0.05). 
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Table 2. Chemical composition of wild and commercial Achillea millefolium L. in fatty 
acids and tocopherols. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nd- not detected; dw- dry weight Caproic acid (C6:0); Caprylic acid (C8:0); Capric acid (C10:0); 
Undecylic acid (C11:0); Lauric acid (C12:0); Tridecanoic acid (C13:0);  Myristic acid (C14:0); 
Myristoleic acid (C14:1); Pentadecanoic acid (C15:0); cis-10-Pentadecenoic acid (C15:1); Palmitic acid 
(C16:0); Palmitoleic acid (C16:1); Heptadecanoic acid (C17:0); Stearic acid (C18:0); Oleic acid (C18:1n-
9c); Linoleic acid (C18:2n-6c); α-Linolenic acid (C18:3n-3); γ-Linolenic acid (C18:3n-6); Arachidic acid 
(C20:0); cis-11-Eicosenoic acid (C20:1); cis-11,14-Eicosadienoic acid (C20:2); Arachidonic acid methyl 
ester (C20:3n-6); Arachidonic acid methyl ester (C20:4n-6); cis-11,14,17-Eicosatrienoic acid and 
Heneicosanoic acid (C20:3n-3+C21:0); Eicosapentaenoic acid (C20:5n-3); Behenic acid (C22:0); Erucic 
acid (C22:1n-9); Tricosanoic acid (C23:0); Lignoceric acid (C24:0). SFA – saturated fatty acids; MUFA – 
 Wild sample Commercial sample 
C6:0 0.72 ± 0.07 0.26 ± 0.03 
C8:0 0.05 ± 0.01 0.36 ± 0.04 
C10:0 0.20 ± 0.02 4.25 ± 0.37 
C11:0 0.05 ± 0.01 0.68 ± 0.01 
C12:0 0.09 ± 0.01 0.53 ± 0.06 
C13:0 0.02 ± 0.00 0.22 ± 0.02 
C14:0 0.05 ± 0.01 1.39 ± 0.12 
C14:1 0.03 ± 0.00 0.27 ± 0.09 
C15:0 0.07 ± 0.00 0.44 ± 0.02 
C15:1 0.09 ± 0.01 0.45 ± 0.04 
C16:0 15.54 ± 0.18 20.70 ± 0.17 
C16:1 0.06 ± 0.00 1.46 ± 0.06 
C17:0 0.26 ± 0.00 0.79 ± 0.02 
C18:0 2.85 ± 0.01 6.49 ± 0.07 
C18:1n-9 28.23 ± 0.11 9.79 ± 0.00 
C18:2n-6 47.16 ± 0.12 26.22 ± 0.10 
C18:3n-6 0.10 ± 0.00 3.66 ± 0.03 
C18:3n-3 0.23 ± 0.02 11.36 ± 0.70 
C20:0 0.72 ± 0.01 1.22 ± 0.04 
C20:1 0.30 ± 0.00 0.49 ± 0.03 
C20:2 0.08 ± 0.04 0.44 ± 0.32 
C20:3n-6 nd 0.20 ± 0.01 
C20:4n-6 0.17 ± 0.02 0.46 ± 0.02 
C20:3n-3+C21:0 0.47 ± 0.01 0.30 ± 0.00 
C20:5n-3 0.96 ± 0.00 0.67 ± 0.17 
C22:0 0.79 ± 0.04 2.18 ± 0.15 
C22:1n-9 0.04 ± 0.01 0.17 ± 0.15 
C23:0 0.14 ± 0.01 0.50 ± 0.02 
C24:0 0.55 ± 0.06 4.04 ± 0.06 
SFA (g/100 g fat) 22.09 ± 0.22b 44.06 ± 0.74a 
MUFA (g/100 g fat) 28.75 ± 0.09a 12.64 ± 0.07b 
PUFA (g/100 g fat) 49.16 ± 0.12a 43.30 ± 0.67b 
α-tocopherol 0.95 ± 0.21a 0.87 ± 0.14a 
β-tocopherol 4.63 ± 0.30a 1.81 ± 0.16b 
γ-tocopherol 13.04 ± 1.38a 12.49 ± 1.21a 
Total tocopherols (mg/100 g dw) 18.62 ± 1.89a 15.16 ± 1.51b 
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monounsaturated fatty acids; PUFA – polyunsaturated fatty acids. In each row different letters mean 
significant differences between species (p<0.05). 
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Table 3. Bioactivity of the methanolic extract, infusion and decoction of wild and commercial Achillea millefolium L.. 
 
 
 Wild sample Commercial sample Positive  control*  Methanolic extract Infusion Decoction Methanolic extract Infusion Decoction 
Antioxidant activity        
DPPH scavenging activity 
(EC50, mg/mL) 
0.50 ± 0.01a 0.40 ± 0.01b 0.25 ± 0.01d 0.37 ± 0.01c 0.22 ± 0.00e 0.20 ± 0.01f 0.04 ± 0.00 
Reducing power  
(EC50, mg/mL) 
0.25 ± 0.01b 0.12 ± 0.00e 0.45 ± 0.00a 0.18 ± 0.01d 0.13 ± 0.00e 0.23 ± 0.00c 0.03 ± 0.00 
β-carotene bleaching inhibition  
(EC50, mg/mL) 
2.08 ± 0.04a 0.59 ± 0.30b 0.18 ± 0.03c  0.30 ± 0.21c 0.53 ± 0.06b 0.22 ± 0.00c 0.003 ± 0.00 
TBARS inhibition  
(EC50, mg/mL)  
0.81 ± 0.09a 0.45 ± 0.14b 0.04 ± 0.01d  0.26 ± 0.02c 0.07 ± 0.01d 0.08 ± 0.01d 0.004 ± 0.00 
Antitumour potential        
MCF-7 (breast carcinoma) 
(GI50, µg/mL) 
17.11 ± 1.05c 14.98  ± 1.68c 64.15 ± 1.75a 48.30 ± 6.07b 64.90 ± 0.79a 64.22 ± 1.02a 0.91 ± 0.04 
NCI-H460 (non-small cell lung cancer) 
(GI50, µg/mL) 
54.24 ± 0.46a 29.17 ± 4.12b 56.24 ± 3.09a 24.64 ± 0.80b 56.26 ± 1.15a 55.71 ± 0.04a 1.42 ± 0.00 
HCT-15 (colon carcinoma) 
(GI50, µg/mL) 
18.88 ± 0.77bc 15.24 ± 2.10c 22.67 ± 3.82ab 13.90 ± 0.75c 26.23 ± 2.26a 24.27 ± 0.16ab 1.91 ± 0.06 
HeLa (cervical carcinoma) 
(GI50, µg/mL) 
39.02 ± 2.90b 20.73 ± 1.16c 52.06 ± 3.87a 19.68 ± 0.47c 47.31 ± 4.84ab 40.96 ± 6.07b 1.14 ± 0.21 
HepG2 (hepatocellular carcinoma) 
(GI50, µg/mL) 
47.14 ± 1.85b 37.60 ± 0.86b 61.26 ± 3.77a 41.12 ± 0.54b 67.46 ± 4.47a 66.13 ± 7.10a 3.22 ± 0.67 
Hepatotoxicity 
PLP2 (GI50, µg/mL) 
58.14 ± 1.05e 57.08 ± 0.97e 314.41 ± 0.24a 250.42 ± 3.30c 118.95 ± 0.29d 288.82 ± 6.30b 2.06 ± 0.03 
 
*Trolox and ellipticine for antioxidant and antitumour activity assays, respectively. EC50 values correspond to the sample concentration achieving 50% of antioxidant activity or 0.5 
of absorbance in reducing power assay. GI50 values correspond to the sample concentration achieving 50% of growth inhibition in human tumour cell lines or in liver primary 
culture PLP2. In each row different letters mean significant differences (p<0.05). 
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Table 4. Retention time (Rt), wavelengths of maximum absorption in the visible region (λmax), mass spectral data, identification and concentration of 
phenolic acids and flavonoids in Achillea millefolium L.. 
 
Peak Rt (min) 
λmax 
 (nm) 
Molecular ion  
[M-H]- (m/z) 
MS2 
(m/z) 
Identification 
1 5.24 326 353 191(100),179(70),173(5),135(53) 3-O-Caffeoylquinic acid 
2 6.51 326 341 179(100) Caffeic acid hexoside 
3 7.30 328 353 191(50),179(88),173(100),135(70) 4-O-Caffeoylquinic acid 
4 8.08 326 353 191(100),179(11),173(8),135(5) 5-O-Caffeoylquinic acid 
5 11.37 330 593 473(19),383(12),353(27) Apigenin C-hexoside-C-hexoside 
6 15.12 332 563 473(9),443(11),383(20),353(21) Apigenin C-hexoside-C-pentoside 
7 15.44 342 563 473(10),443(20),383(15),353(27) Apigenin C-glucose-C-pentoside 
8 16.36 350 447 357(83),327(88),297(30),285(16) Luteolin 6-C-glucoside 
9 17.37 356 595 301(100) Quercetin O-pentosyl-hexoside 
10 17.66 344 463 301(100) Quercetin O-hexoside 
11 18.17 334 695 651(100),609(3),447(16),301(17) Quercetin O-malonylhexosyl-rhamnoside  
12 19.47 350 579 417(7),285(49) Kaempferol O-pentosyl-hexoside 
13 19.61 352 609 301(100) Quercetin 3-O-rutinoside 
14 20.45 340 593 269(100) Apigenin O-dihexoside 
15 20.64 336 477 315(100) Isorhamnetin O-hexoside 
16 21.01 328 515 353(71),335(34),299(3),255(4),203(8),191(41),179(70),173(93),161(15),135(32) 3,4-O-dicaffeoylquinic acid 
17 21.37 346 505 301(100) Quercetin O-acetylhexoside 
18 22.35 352 505 301(100) Quercetin  O-acetylhexoside 
19 22.64 328 515 353(96),335(4),191(100),179(70),173(8),161(14),135(22) cis 3,5-O-dicaffeoylquinic acid  
20 22.88 330 515 353(96),335(10),191(100),179(68),173(7),161(15),135(15) trans 3,5-O-dicaffeoylquinic acid  
21 23.46 344 563 269(100) Apigenin O-pentosyl-hexoside 
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22 25.41 328 515 353(17),335(3),299(5),255(3),203(15),191(49),179(57),173(79),161(14),135(17) 4,5-O-dicaffeoylquinic acid 
23 25.53 332 431 269(100) Apigenin 7-O-glucoside 
24 26.21 350 489 285(100) Luteolin  O-acetylhexoside 
25 28.25 362 519 315(100) Isorhamnetin  O-acetylhexoside 
26 29.22 338 473 269(100) Apigenin  O-acetylhexoside 
27 30.34 336 473 269(100) Apigenin  O-acetylhexoside 
28 31.20 340 473 269(100) Apigenin  O-acetylhexoside 
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Table 5. Phenolic compounds quantification in the methanolic extract (mg/g extract), infusion (mg/g infusion) and decoction (mg/g decoction) of 
wild and commercial Achillea millefolium L.. 
 Wild sample Commercial sample 
 Methanolic extract Infusion Decoction Methanolic extract Infusion Decoction 
Extraction yield (%) 20.39 ± 0.91 21.50 ± 1.02 13.31 ± 0.52 21.32 ± 1.10 22.72 ± 0.48 12.64 ± 0.27 
1 0.86 ± 0.04 0.96 ± 0.05 1.22 ± 0.04 0.96 ± 0.07 1.28 ± 0.12 0.89 ± 0.05 
2 0.28 ± 0.01 0.21 ± 0.03 0.09 ± 0.01 0.16 ± 0.00 0.21 ± 0.03 0.57 ± 0.03 
3 1.01 ± 0.10 1.00 ± 0.00 0.65 ± 0.01 0.31 ± 0.04 0.65 ± 0.04 0.67 ± 0.03 
4 24.20 ± 0.18 24.58 ± 0.30 12.76 ± 0.12 13.99 ± 0.64 19.34 ± 0.85 15.24 ± 0.38 
5 0.52 ± 0.01 0.76 ± 0.06 0.56 ± 0.05 1.73 ± 0.14 2.28 ± 0.16 2.31 ± 0.10 
6 0.75 ± 0.10 0.73 ± 0.02 0.43 ± 0.00 1.18 ± 0.11 1.68 ± 0.13 1.90 ± 0.13 
7 0.26 ± 0.02 0.22 ± 0.02 0.17 ± 0.00 0.27 ± 0.01 0.34 ± 0.02 0.42 ± 0.03 
8 0.12 ± 0.00 0.12 ± 0.00 0.08 ± 0.00 0.28 ± 0.01 0.32 ± 0.02 0.43 ± 0.05 
9 0.15 ± 0.00 0.10 ± 0.00 0.08 ± 0.00 0.35 ± 0.04 0.34 ± 0.01 0.72 ± 0.05 
10 2.71 ± 0.12 1.15 ± 0.01 0.29 ± 0.00 0.16 ± 0.04 0.21 ± 0.03 0.18 ± 0.01 
11 0.44 ± 0.02 0.19 ± 0.01 0.12 ± 0.01 0.28 ± 0.03 0.22 ± 0.01 0.31 ± 0.03 
12 0.29 ± 0.02 0.32 ± 0.01 0.31 ± 0.02 0.49 ± 0.00 0.63 ± 0.04 0.63 ± 0.01 
13 0.94 ± 0.03 0.79 ± 0.01 0.10 ± 0.00 0.64 ± 0.02 0.79 ± 0.06 0.86 ± 0.02 
14 0.61 ± 0.06 0.98 ± 0.02 0.51 ± 0.06 1.13 ± 0.11 1.52 ± 0.14 1.54 ± 0.05 
15 0.34 ± 0.04 0.68 ± 0.04 0.28 ± 0.02 0.29 ± 0.03 0.42 ± 0.07 0.50 ± 0.01 
16 5.45 ± 0.19 5.69 ± 0.20 1.60 ± 0.09 4.41 ± 0.27 5.34 ± 0.55 6.16 ± 0.04 
17 1.61 ± 0.05 1.88 ± 0.02 0.87 ± 0.06 nd nd nd 
18 0.76 ± 0.10 0.68 ± 0.09 0.23 ± 0.03 0.55 ± 0.06 0.77 ± 0.08 0.18 ± 0.03 
19 35.73 ± 0.44 28.05 ± 0.16 7.40 ± 0.29 25.30 ± 0.24 28.45 ± 2.41 27.83 ± 0.03 
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20 26.02 ± 0.05 19.96 ± 0.53 6.85 ± 0.05 10.50 ± 0.24 13.46 ± 0.87 11.98 ± 0.28 
21 1.13 ± 0.13 1.06 ± 0.01 0.39 ± 0.04 0.88 ± 0.07 0.82 ± 0.32 0.71 ± 0.00 
22 10.24 ± 0.02 8.87 ± 0.22 1.94 ± 0.03 10.75 ± 0.67 12.17 ± 0.31 13.53 ± 0.37 
23 1.43 ± 0.01 1.20 ± 0.18 0.57 ± 0.00 2.65 ± 0.06 2.56 ± 0.35 2.58 ± 0.10 
24 6.21 ± 0.59 5.32 ± 0.05 2.80 ± 0.09 6.49 ± 0.10 7.22 ± 0.04 6.80 ± 0.44 
25 0.15 ± 0.01 0.16 ± 0.00 0.24 ± 0.01 0.10 ± 0.00 0.08 ± 0.01 0.07 ± 0.00 
26 0.36 ± 0.02 0.35 ± 0.01 0.15 ± 0.01 0.64 ± 0.08 0.75 ± 0.08 0.68 ± 0.03 
27 5.45 ± 0.35 5.89 ± 0.04 2.72 ± 0.07 9.85 ± 0.45 12.12 ± 1.04 9.47 ± 0.29 
28 0.35 ± 0.00 0.37 ± 0.00 0.25 ± 0.04 0.69 ± 0.06 0.71 ± 0.07 0.79 ± 0.02 
TPA 103.80 ± 0.45a 89.32 ± 0.12b 32.52 ± 0.52e 66.39 ± 2.18d 80.91 ± 5.19c 76.88 ± 0.39c 
TF 24.56 ± 0.36d 22.96 ± 0.10d 11.14 ± 0.05e 28.63 ± 1.01c 33.78 ± 1.98a  31.09 ± 0.47b 
TP 128.36 ± 0.0a 112.28 ± 0.22bc 43.66 ± 0.57e 95.02 ± 3.19d 114.69 ± 7.17b 107.97 ± 0.86c 
 
nd- not detected. TPA- Total phenolic acids; TF- Total flavonoids; TP- Total phenolic compounds. In each row different letters mean significant differences (p<0.05). 
 
 
 
 
 
 
